• Journal of Gastric Cancer
• /
• 제15권3호
• /
• pp.191-200
• /
• 2015

Purpose: This study evaluated the functional and oncological outcomes of proximal gastrectomy (PG) in comparison with total gastrectomy (TG) for upper-third early gastric cancer (EGC). Materials and Methods: The medical records of upper-third EGC patients who had undergone PG (n=192) or TG (n=157) were reviewed. The PG group was further subdivided into patients who had undergone conventional open PG (cPG; n=157) or modified laparoscopy-assisted PG (mLAPG; n=35). Patients who had undergone mLAPG had a longer portion of their intra-abdominal esophagus preserved than patients who had undergone cPG. Surgical morbidity, recurrence, long-term nutritional status, and the incidence of reflux esophagitis were compared between the groups. Results: The rate of postoperative complications was significantly lower for PG than TG (16.7% vs. 31.2%), but the five-year overall survival rate was comparable between the two groups (99.3% vs. 96.3%). Postoperative levels of hemoglobin and albumin were significantly higher for patients who had undergone PG. However, the incidence of reflux esophagitis was higher for PG than for TG (37.4% vs. 3.7%; P<0.001). mLAPG was related to a lower incidence of reflux esophagitis after PG (P<0.001). Conclusions: Compared to TG, PG showed an advantage in terms of postoperative morbidity and nutrition, and there was a comparable prognosis between the two procedures. Preserving the intra-abdominal esophagus may lower the incidence of reflux esophagitis associated with PG.

• Journal of Gastric Cancer
• /
• 제13권4호
• /
• pp.242-246
• /
• 2013

Purpose: Reoperations after gastrectomy for gastric cancer are performed for many types of complications. Unexpected reoperations may cause mental, physical, and financial problems for patients. The aim of the present study was to evaluate the causes of reoperations and to develop a strategic decision-making process for these reoperations. Materials and Methods: From September 2002 through August 2010, 6,131 patients underwent open conventional gastrectomy operations at Samsung Medical Center. Of these, 129 patients (2.1%) required reoperation because of postoperative complications. We performed a retrospective analysis of the patients using an electronic medical record review. Statistical data were analyzed to compare age, sex, stage, type of gastrectomy, length of operation, size of tumor, and number of lymph node metastasis between patients who had been operated and those who had not. Results: The variables of age, sex, tumor stage, type of gastrectomy, length of operation, and number of lymph node metastases did not differ between the 2 groups. However, the mean tumor size in the reoperation group was greater than that in the non-reoperation group ($5.0{\pm}3.7$ [standard deviation] versus $4.1{\pm}2.9$, P=0.007). The leading cause of reoperation was surgical-site infection (n=49, 0.79%). Patients with intra-abdominal bleeding were operated on again in the shortest period after the initial gastrectomy ($6.3{\pm}4.2$ days). Patients with incisional hernia were not reoperated on until after $208.3{\pm}81.0$ days, the longest postoperative period. Conclusions: Tumor size was the major variable leading to reoperation after gastrectomy for gastric cancer. The most common complication requiring the reoperation was a surgical site-related complication.

• Journal of Gastric Cancer
• /
• 제13권4호
• /
• pp.214-225
• /
• 2013

Purpose: Peritoneal lavage cytology is part of the routine staging workup for patients with advanced gastric cancer. However, no quality assurance study has been conducted to show variations or biases in peritoneal lavage cytology results. The aim of this study was to demonstrate a test execution variation in peritoneal lavage cytology between investigating surgeons. Materials and Methods: A prospective cohort study was designed for determination of the positive rate of peritoneal lavage cytology using a liquid-based preparation method in patients with potentially curable advanced gastric cancer (cT2~4/N0~2/M0). One hundred thirty patients were enrolled and underwent laparotomy, peritoneal lavage cytology, and standard gastrectomy, which were performed by 3 investigating surgeons. Data were analyzed using the chi-square test and a logistic regression model. Results: The overall positive peritoneal cytology rate was 10.0%. Subgroup positive rates were 5.3% in pT1 cancer, 2.0% in pT2/3 cancer, 11.1% in pT4a cancer, and 71.4% in pT4b cancer. In univariate analysis, positive peritoneal cytology showed significant correlation with pT stage, lymphatic invasion, vascular invasion, ascites, and the investigating surgeon. We found the positive rate to be 2.1% for surgeon A, 10.2% for surgeon B, and 20.6% for surgeon C (P=0.024). Multivariate analysis identified pT stage, ascites, and the investigating surgeon to be significant risk factors for positive peritoneal cytology. Conclusions: The peritoneal lavage cytology results were significantly affected by the investigating surgeon, providing strong evidence of test execution variation that could be related to poor diagnostic accuracy and stage migration in patients with advanced gastric cancer.

• Journal of Gastric Cancer
• /
• 제17권1호
• /
• pp.52-62
• /
• 2017

Purpose: The Trastuzumab for gastric cancer (GC) trial identified human epidermal growth factor receptor 2 (HER2) as a predictor of successful treatment with trastuzumab (HER2 receptor targeting agent) among patients with advanced/metastatic GC. To date, the prevalence of HER2 overexpression in the Korean population is unknown. The present study aimed to assess the incidence of HER2 positivity among GC and gastroesophageal (GE) junction cancer samples and the relationship between HER2 overexpression and clinicopathological characteristics in Korean patients. Materials and Methods: Tumor samples collected from 1,695 patients with histologically proven GC or GE junction enrolled at 14 different hospitals in Korea were examined. After gathering clinicopathological data of all patients, HER2 status was assessed by immunohistochemistry (IHC) at each hospital, and IHC 2+ cases were subjected to silver-enhanced in situ hybridization at 3 central laboratories. Results: A total of 182 specimens tested positive for HER2, whereas 1,505 tested negative. Therefore, the overall HER2-positive rate in this study was 10.8% (95% confidence interval=9.3%-12.3%). The HER2-positive rate was higher among intestinal-type cases (17.6%) than among other types, and was higher among patients older than 70 years and 50 years of age, compared to other age groups. Conclusions: Our evaluation of the HER2 positivity rate (10.8%) among Korean patients with GC and GE junction indicated the necessity of epidemiological data when conducting studies related to HER2 expression in GC and GE junction.

• Journal of Gastric Cancer
• /
• 제17권1호
• /
• pp.74-87
• /
• 2017

Purpose: Neoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes. Materials and Methods: A retrospective analysis was performed using an academic cancer center patient cohort diagnosed with locally advanced gastric cancer between January 2012 and December 2014 and treated with neoadjuvant chemotherapy. We analyzed body composition (skeletal muscle and visceral fat index) in axial computed tomography images. Results: A total of 48 patients met the inclusion criteria. The mean age was $68{\pm}10years$, and 33 patients (69%) were men. Dose-limiting toxicity was observed in 22 patients (46%), and treatment was terminated early owing to toxicity in 17 patients (35%). Median follow-up was 17 months. Sarcopenia and sarcopenic obesity were found at diagnosis in 23% and 10% of patients, respectively. We observed an association between termination of chemotherapy and both sarcopenia (P=0.069) and sarcopenic obesity (P=0.004). On multivariate analysis, the odds of treatment termination were higher in patients with sarcopenia (odds ratio=4.23; P=0.050). Patients with sarcopenic obesity showed lower overall survival (median survival of 6 months [95% confidence interval {CI}=3.9-8.5] vs. 25 months [95% CI=20.2-38.2]; log-rank test P=0.000). Conclusions: Sarcopenia and sarcopenic obesity were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.

• Journal of Gastric Cancer
• /
• 제18권3호
• /
• pp.287-295
• /
• 2018

Purpose: The surgical outcomes of end-stage renal disease (ESRD) patients undergoing radical gastrectomy for gastric cancer were inferior compared with those of non-ESRD patients. This study aimed to evaluate the short- and long-term surgical outcomes of ESRD patients undergoing laparoscopic gastrectomy (LG) and open gastrectomy (OG) for gastric cancer. Materials and Methods: Between 2004 and 2014, 38 patients (OG: 21 patients, LG: 17 patients) with ESRD underwent gastrectomy for gastric cancer. Comparisons were made based on the clinicopathological characteristics, surgical outcomes, and long-term survival rates. Results: No significant differences were noted in the clinicopathological characteristics of either group. LG patients had lower estimated blood loss volumes than OG patients (LG vs. OG: 94 vs. 275 mL, P=0.005). The operation time and postoperative hospital stay were similar in both the groups. The postoperative morbidity for LG and OG patients was 41.1% and 33.3%, respectively (P=0.873). No significant difference was observed in the long-term overall survival rates between the 2 groups (5-year overall survival, LG vs. OG: 82.4% vs. 64.7%, P=0.947). Conclusions: In ESRD patients, LG yielded non-inferior short- and long-term surgical outcomes compared to OG. Laparoscopic procedures might be safely adopted for ESRD patients who can benefit from the advantages of minimally invasive surgery.

• Tuberculosis and Respiratory Diseases
• /
• 제68권1호
• /
• pp.1-5
• /
• 2010

Background: To analyze the result of $^{18}F-FDG$ positron emission tomography (PET) in patients with a concomitant malignancy and tuberculoma in a tuberculosis (TB)-endemic area. Methods: Twelve patients with a concomitant malignancy and tuberculoma, who underwent whole-body $^{18}F-FDG$ PET, were evaluated retrospectively. The maximal standardized uptake values (SUVmax) of the malignancy and tuberculoma were compared. In 6 patients, $^{18}F-FDG$ PET was repeated during the anti-TB treatment and the changes in SUVmax were analyzed. Results: Of the 12 patients, 10 were male. The mean age was $67.2{\pm}7.9$ years. Tuberculomas were located in the lung (n=10) and lymph nodes (n=2), and tumors were located in the lung (n=6), colon (n=3), stomach (n=1), ovary (n=1) and liver (n=1). Although the mean SUVmax of malignant lesions was higher than that of tuberculomas ($5.2{\pm}3.2$ vs $3.5{\pm}2.0$), the difference was not significant. In 4 patients, the SUVmax was higher in the tuberculoma than the tumor. After anti-TB treatment in 6 patients, the mean SUVmax of the tuberculomas decreased significantly, from $3.5{\pm}2.0$ to $1.6{\pm}0.9$ (p=0.028). Conclusion: In patients with a concomitant malignancy and tuberculoma, SUVmax alone could not differentiate between them. However, $^{18}F-FDG$ PET may be useful in monitoring the response to anti-TB treatment.

• Journal of Hospice and Palliative Care
• /
• 제10권1호
• /
• pp.29-34
• /
• 2007

목적: 본 연구는 위암과 폐암 말기로 진단받고 동일 병원에 입원하여 호스피스 대상자와 비대상자로 치료를 받다가 사망한 환자 114명을 대상으로 사망시점부터 14일 전까지의 진료비를 분석하여 양 대상을 비교하는데 있다. 방법: 진료비 분석에 대한 후향적 조사연구 설계로서 진료비 분석에 대한 도구는 C 대학 K 병원의 진료비 계산서 영수증을 기초로 하여 작성된 11개 항목에 대한 각각의 진료비 및 총액이었다. 결과: 호스피스 대상자의 진료비가 비 호스피스 대상자에 비해 낮았는데 특히 고단위 영양제, 마약성 진통제, 간호처치료, 방사선 검사, 혈액검사항목에서 통계적으로 유의하게 낮았다. 또한 호스피스 대상자 중에서는 호스피스 전담의의 유무에 따라 진료비의 총액에는 차이가 없었으나 기타 진통제 항목에서 전담의가 있었던 시기가 전담의가 없었던 시기에 비해 진료비용이 유의하게 높았다. 결론: 본 연구결과 동일기간 내 호스피스 대상자의 진료비용이 비 대상자에 비해 약 53%에 지나지 않음을 알 수 있어 범국가적인 차원의 호스피스 제도화 도입이 시급하다고 본다.

• Tuberculosis and Respiratory Diseases
• /
• 제65권2호
• /
• pp.105-109
• /
• 2008

연구배경: Fascin은 세포 운동에 관여하는 액틴 결합 단백질로서 정상적인 상피세포에는 증가되어 있지 않으며, 일부 악성종양에서 fascin이 증가되어 있다는 보고가 있다. 본 연구는 비소세포폐암 환자의 조직에서 fascin 발현을 조사하고 fascin이 예후 인자로 역할을 하는지를 알아보고자 하였다. 방 법: 제 1기 비소세포폐암으로 근치적 절제수술을 받고 추적조사가 가능했던 환자 81명의 조직에서 fascin 발현을 면역조직화학 염색 방법으로 조사하였다. 결 과: Fasin 발현은 전체 81예 중 59예(73%)에서 양성이었다. Fascin 발현 정도에 따른 5년 생존율은 fascin 발현 음성군에서 68%, fascin 저발현군에서 76%, fascin고발현군에서 79%으로 각 군간에 유의한 차이가 없었다(p=0.86). 결 론: Fascin발현이 비소세포폐암으로 근치적 수술을 받은 환자에서 예후 인자로서 역할을 하는지 알아보았으나 통계학적으로 유의한 관련성이 없었다.

• Journal of Gastric Cancer
• /
• 제10권1호
• /
• pp.34-39
• /
• 2010

목적: 위암 환자에 있어서 근치적 위절제술 후, 위 절제 범위에 따라 삶의 질의 차이가 있다고 한다. 본 연구에서는 수술 후 장시간 경과 후 절제 범위에 따른 삶의 질의 차이를 확인했다. 대상 및 방법: 위암으로 근치적 위절제술을 받은 환자 중, 수술 후 5년이 지나 정기검진을 위해 외래를 방문한 166명을 대상으로 하여, EORTC QLQ-C30 3판과 EORTC QLQSTO22의 한국어판을 이용하여 삶의 질을 평가하였다. 결과: EORTC QLQ-C30으로 수술 후 5년에 평가한 삶의 질은, 육체적, 역할, 정서적, 인지, 사회적 기능 척도 및 피로감, 통증, 호흡곤란, 설사, 경제적 부담감의 척도에서 위아전절제술을 받은 후에 나은 삶의 질을 보이는 경향이 있었으나 통계학적으로 유의한 수준은 아니었다. 전체적인 건강 및 삶의 질, 오심과 구토, 수면장애, 식욕감퇴, 변비의 척도에서는 위전절제술을 받은 후에 더 나은 삶의 질을 보이는 경향이 있었으나 통계학적으로 유의한 수준은 아니었다. EORTC QLQ-STO22로 수술 후 5년에 평가한 삶의 질은, 모든 척도에서 위아전절제술을 받은 후에 더 나은삶의 질을 보이는 경향이 있었으나 통계학적으로 유의한 수준은 아니었다. 결론: 수술 후 단기적인 삶의 질의 차이는 있지만, 위암 완치 후에도 장기적으로 지속되는 삶의 질의 악화를 염려하여, 근치적 위절제술의 절제 범위를 축소할 필요는 없겠으며, 종양학적 원칙에 입각한 수술이 필요하겠다.